Zhao Haibo, Kitaura Hideki, Sands Mark S, Ross F Patrick, Teitelbaum Steven L, Novack Deborah Veis
Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
J Bone Miner Res. 2005 Dec;20(12):2116-23. doi: 10.1359/JBMR.050724. Epub 2005 Jul 25.
We show that mice lacking beta3 integrin are protected from OVX-induced bone loss. Using a lentiviral-based strategy to express beta3 mutants in beta3(-/-) mice, we also show that beta3(S752), but not beta3(Y747/Y759), is important for osteoclastic bone resorption in vivo.
Mice lacking the beta3 integrin have dysfunctional osteoclasts and therefore accumulate bone mass with age. Thus, the alphavbeta3 integrin is a potential anti-osteoporosis target. Identifying components of the beta3 integrin that determine its function in vivo is essential for therapeutically exploiting the antiresorptive properties of alphavbeta3.
We used DXA and histomorphometry to assess bone loss after ovariectomy in wildtype and beta3 integrin null mice. We used lentiviral vectors carrying various human beta3 (hbeta3) integrin constructs to transduce beta3(-/-) bone marrow and reconstituted lethally irradiated beta3(-/-) mice with the transduced marrow. The expressed constructs include the intact integrin and two mutants, namely hbeta3(Y747F/Y759F) and hbeta3(S752P), each of which induces the bleeding dyscrasia, Glanzmann's thrombasthenia, in humans. Two months after transplantation, the expression of hbeta3 was measured by flow cytometry of marrow-derived macrophages. Osteoclast differentiation and function were assessed ex vivo by TRACP and actin-ring staining, respectively. Reconstituted mice were ovariectomized, and bone loss was assessed by DXA, histomorphometry, and serum TRACP5b assay.
beta3(-/-) mice are protected from ovariectomy-induced bone loss, showing no difference in BMD compared with sham-operated controls. We successfully expressed hbeta3 integrins in beta3(-/-) hosts using lentiviral transduction of bone marrow. Two months after transplantation, 25-35% of marrow-derived macrophages expressed the hbeta3 constructs. Similar to its effect in vitro, hbeta3(WT) completely rescued the osteoclast and platelet phenotype of beta3(-/-) mice. Whereas platelet function remained deranged in beta3(-/-) mice overexpressing hbeta3(Y747F/Y759F), osteoclast function was fully restored. In contrast, beta3(-/-) mice expressing hbeta3(S752P) continued to exhibit prolonged bleeding times and dysfunctional osteoclasts in vitro and ex vivo. Most importantly, hbeta3(WT) and hbeta3(Y747F/Y759F) transplanted mice underwent equivalent ovariectomy-induced bone loss, whereas, like those bearing the control vector, hbeta3(S752P) transplanted mice were protected.
Functional beta3 integrin is required for ovariectomy-induced bone loss. beta3(S752), but not beta3(Y747/Y759), is critical for osteoclast function in vivo.
我们发现缺乏β3整合素的小鼠可免受去卵巢诱导的骨质流失影响。通过基于慢病毒的策略在β3基因敲除小鼠中表达β3突变体,我们还发现β3(S752)而非β3(Y747/Y759)对体内破骨细胞性骨吸收很重要。
缺乏β3整合素的小鼠破骨细胞功能失调,因此随着年龄增长骨量增加。因此,αvβ3整合素是一个潜在的抗骨质疏松靶点。确定β3整合素中决定其体内功能的成分对于治疗性利用αvβ3的抗吸收特性至关重要。
我们使用双能X线吸收法(DXA)和组织形态计量学评估野生型和β3整合素基因敲除小鼠去卵巢后的骨质流失情况。我们使用携带各种人β3(hβ3)整合素构建体的慢病毒载体转导β3基因敲除小鼠的骨髓,并用转导后的骨髓重建经致死性照射的β3基因敲除小鼠。表达的构建体包括完整的整合素和两个突变体,即hβ3(Y747F/Y759F)和hβ3(S752P),这两个突变体在人类中均会引发出血性疾病——血小板无力症。移植两个月后,通过对骨髓来源巨噬细胞进行流式细胞术检测hβ3的表达。分别通过抗酒石酸酸性磷酸酶(TRACP)和肌动蛋白环染色在体外评估破骨细胞的分化和功能。对重建后的小鼠进行去卵巢手术,并通过DXA、组织形态计量学和血清TRACP5b检测评估骨质流失情况。
β3基因敲除小鼠可免受去卵巢诱导的骨质流失影响,与假手术对照组相比,骨密度无差异。我们通过慢病毒转导骨髓成功在β3基因敲除宿主中表达了hβ3整合素。移植两个月后,25% - 35%的骨髓来源巨噬细胞表达了hβ3构建体。与在体外的作用类似,hβ3(野生型)完全挽救了β3基因敲除小鼠的破骨细胞和血小板表型。虽然在过表达hβ3(Y747F/Y759F)的β3基因敲除小鼠中血小板功能仍然紊乱,但破骨细胞功能完全恢复。相比之下,表达hβ3(S752P)的β3基因敲除小鼠在体内外均继续表现出出血时间延长和破骨细胞功能失调。最重要的是,移植hβ3(野生型)和hβ3(Y747F/Y759F)的小鼠经历了相当程度的去卵巢诱导的骨质流失,而移植hβ3(S752P)的小鼠则像携带对照载体的小鼠一样受到保护。
功能性β3整合素是去卵巢诱导的骨质流失所必需的。β3(S752)而非β3(Y747/Y759)对体内破骨细胞功能至关重要。